Common Contracts
5 similar Underwriting Agreement contracts by Sunshine Biopharma, Inc, China SXT Pharmaceuticals, Inc., Ra Medical Systems, Inc., T1V, Inc.
UNDERWRITING AGREEMENT Dated [____________] [__], 2023 Between T1V, INC. (a Delaware corporation), SELLING STOCKHOLDERS OF T1V, INC. named on Schedule II attached hereto (for the sole purpose of the Over-Allotment Option) And EF HUTTON, Division of...Underwriting Agreement • January 24th, 2023 • T1V, Inc. • Services-computer programming, data processing, etc. • New York
The undersigned, T1V, Inc., a company incorporated under the laws of the State of Delaware (the “Company”), and certain stockholders of the Company (the “Selling Stockholders”) named on Schedule II attached hereto (for the sole purpose of the Over-Allotment Option), hereby confirm their agreement (this “Agreement”) with the several underwriters (such underwriters, including the Representative (as defined below), the “Underwriters” and each an “Underwriter”) named in Schedule I hereto for which EF Hutton, division of Benchmark Investments, LLC (“EF Hutton”), is acting as representative to the several Underwriters (in such capacity, the “Representative” and if there are no Underwriters other than the Representative, references to multiple Underwriters shall be disregarded and the term Representative as used herein shall have the same meaning as Underwriter) on the terms and conditions set forth herein. References made to Selling Stockholders shall relate solely to the Over-Allotment Opti
UNITS Sunshine Biopharma, Inc. UNDERWRITING AGREEMENTUnderwriting Agreement • February 14th, 2022 • Sunshine Biopharma, Inc • Services-commercial physical & biological research • New York
The undersigned, Sunshine Biopharma, Inc., a corporation formed under the laws of the State of Colorado (collectively, with its Subsidiaries, the “Company”), hereby confirms its agreement (this “Agreement”) with Aegis Capital Corp. (“Aegis” or the “Underwriter”) on the terms and conditions set forth herein. The offering and sale of the Securities contemplated by this Agreement is referred to herein as the “Offering”.
UNITS Sunshine Biopharma, Inc. UNDERWRITING AGREEMENTUnderwriting Agreement • February 9th, 2022 • Sunshine Biopharma, Inc • Services-commercial physical & biological research • New York
The undersigned, Sunshine Biopharma, Inc., a corporation formed under the laws of the State of Colorado (collectively, with its Subsidiaries, the “Company”), hereby confirms its agreement (this “Agreement”) with Aegis Capital Corp. (“Aegis” or the “Underwriter”) on the terms and conditions set forth herein. The offering and sale of the Securities contemplated by this Agreement is referred to herein as the “Offering”.
RA MEDICAL SYSTEMS, INC. UNDERWRITING AGREEMENTUnderwriting Agreement • February 9th, 2022 • Ra Medical Systems, Inc. • Surgical & medical instruments & apparatus • New York
The undersigned, Ra Medical Systems, Inc., a Delaware corporation (the “Company”), hereby confirms its agreement (this “Agreement”) with the several underwriters, if any (such underwriters, including the Representative (as defined below), the “Underwriters” and each an “Underwriter”) named in Schedule I hereto for which Ladenburg Thalmann & Co. Inc. is acting as representative (the “Representative” and if there are no Underwriters other than the Representative, references to multiple Underwriters shall be disregarded and the term Representative as used herein shall have the same meaning as Underwriter) on the terms and conditions set forth herein.
CHINA SXT PHARMACEUTICALS, INC. UNDERWRITING AGREEMENTUnderwriting Agreement • January 21st, 2022 • China SXT Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
The undersigned, China SXT Pharmaceuticals, Inc., a British Virgin Islands corporation, (collectively with its Subsidiaries (as defined below) the “Company”), hereby confirms its agreement (this “Agreement”) with Aegis Capital Corp. (the “Underwriter”).
